AZNAstraZeneca PLC
$171.49+3.4% 1Y
$171.49
$155.6052 weeks$208.62
Is the price fair?
What AZN's price assumes
AstraZeneca PLC has no trailing P/E on file, so the price is measured against sales instead: 3.07× revenue.
3.07
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 4.76
Price / book · as of 2025-Q2
- EV / sales
- 3.44
EV / sales
Details›
- Price / bookas of 2025-Q2
- 4.76
- EV / EBITas of 2025-Q2
- 17.0
- EV / salesas of 2025-Q2
- 3.44
- Market capitalisation1.55 billion shares, average to Dec 31, 2025
- $265.8B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, General
Ranks #5 of 7 by RyuScore